Laurus Labs receives Sebi Nod for IPO Laurus Labs, the Drug ingredients maker has been given the approval by markets regulator Sebi's go ahead to float an initial public offering. Hyderabad-based firm had filed IPO papers with Sebi in the month of August. The markets regulator issued its final view on October 10 on the draft offer documents, which is mandatory for any company to launch the public offer. Laurus Labs has filed its DRHP (draft red herring prospectus) with SEBI (Securities and Exchange Board of India) to float its initial public offering (IPO), since the Visakhapatnam-based drug ingredients maker wishes to join a string of healthcare companies that have made remarkable debuts on stock markets over the past year. The suggested IPO is a mix of a fresh issue of shares totaling up to Rs 300 crore and an offer for sale by shareholders involving private equity firm Warburg Pincus, which is part-exiting. The drug firm is eyeing to raise money to repay term loans and for general corporate purposes.
For the last few years many healthcare companies have floated IPOs successfully including diagnostics chains Thyrocare and Lal Path Labs and hospital chain Narayana Hrudayala , which was listed previously this year.
Here's a snapshot of Lauras Labs and the issue Size- According to the draft papers, the public issue constitutes fresh issue of shares valued at Rs. 300 crore and an offer for sale of 24,844,240 equity scrips by the current shareholders, which includes Warburg Pincus group and Eight Roads Ventures.
Object of the Issue- Proceed of this issue would be utilized for the payment of loans and for general corporate purposes. The firm plans to use the money for partial repayment of long-term borrowings. Approximately Rs 1,115.28 crore is the aggregate bank loans that the firm has availed and was outstanding as of 30 June 2016. This included foreign currency loan of $41.82 million .
Bankers- This issue is being managed by Citigroup Global Markets India Kotak Mahindra Capital Company, Jefferies India and SBI Capital Markets. In the month of June, Aster DM Healthcare Ltd, which operates hospitals in India and the Middle East, also filed its DRHP with the capital markets regulator. One more healthcare company, eye-care chain New Delhi Centre For Sight, has also been given SEBI approval for its IPO. Laurus Labs is a noted research and development driven pharma company in India, with a leadership position in generic active pharmaceutical ingredients for select, high-growth therapeutic areas of anti-retrovirals and Hepatitis C. At present, the company now also has a rising synthesis and nutraceutical/cosmeceutical ingredients businesses, and a combined generics finished dosage forms business. The company functions three manufacturing facilities in Visakhapatnam, Andhra Pradesh. It is setting up two new
manufacturing facilities, one for potent APIs and the other for APIs, intermediates and ingredients.
Disclaimer The investment advice or guidance provided by way of recommendations, reports or other ways are solely the personal views of the research team. Users are advised to use the data for the purpose of information and rely on their own judgment while making investment decision. Dynamic Equities Pvt. Ltd - SEBI Investment Advisory Reg. No.: INA300002022
Disclosure Dynamic Equities Pvt. Ltd. is a member of NSE, BSE, MCX SX and a DP with NSDL & CDSL. It is also engaged in Investment Advisory Services and Portfolio Management Services. Dynamic Commodities Pvt. Ltd., associate company, is a member of MCX & NCDEX. We declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered. SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise letters or levied minor penalty on for certain operational deviations. Answers to the Best of our knowledge and belief of Dynamic/ its Associates/ Research Analyst: DYNAMIC/its Associates/ Research Analyst/ his Relative: Do not have any financial interest / any actual/beneficial ownership in the subject company. Do not have any other material conflict of interest at the time of publication of the research report Have not received any compensation from the subject company in the past twelve months Have not managed or co-managed public offering of securities for the subject company. Have not received any compensation for brokerage services or any products / services or any compensation or other benefits from the subject company, nor engaged in market making activity for the subject company Have not served as an officer, director or employee of the subject company
Article Written by Madhurima Chowdhury